COMPASS Pathways (CMPS) Investor presentation summary

Market opportunity and unmet need

• Large underserved populations in the U.S.: 4 million with treatment-resistant depression (TRD) and 13 million with PTSD.

• TRD patients experience longer depressive episodes, higher mortality, and greater work time loss compared to MDD.

• Only one approved medicine for TRD, highlighting significant unmet need.

Clinical development and efficacy

• Two pivotal Phase 3 trials in TRD (COMP005 and COMP006) achieved primary endpoints with high statistical significance at week 6.

• Rapid onset of effect observed the day after administration, with durable clinical benefits through at least 26 weeks.

• 25% (COMP005) and 39% (COMP006) of participants achieved clinically meaningful reduction in depression scores at week 6.

• Second administration in COMP006 showed potential for deeper treatment effect.

Safety and tolerability

• COMP360 demonstrated a generally safe and well-tolerated profile in clinical trials.

• Most adverse events were mild, occurred on the day of administration, and resolved quickly.

• Common side effects included headache, nausea, fatigue, anxiety, and visual hallucination.